$7.32+0.26 (+3.68%)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Wave Life Sciences Ltd. in the Healthcare sector is trading at $7.32. The stock is currently near its 52-week low of $5.02, remaining 28.3% below its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why WVE maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multipl...
Wave Life Sciences (WVE) has drawn investor attention after recent share price swings, including a loss of around 54% year to date and a decline of about 43% over the past 3 months. See our latest analysis for Wave Life Sciences. Despite the steep year to date share price decline and a weak 90 day share price return, the recent 30 day share price gain and positive 3 year total shareholder return suggest shifting momentum around growth prospects and perceived risk. If you are comparing Wave...
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) ranks among the most profitable biotech stocks to buy now. Following comments on Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)’s obesity and metabolic illness initiatives, TD Cowen reiterated its Buy rating on March 26. The firm pointed out that Wave Life Sciences published more data from Arrowhead’s ARO-INHBE program, demonstrating that, despite the higher […]
Moby summary of Wave Life Sciences Ltd.'s Q1 2026 earnings call
WAVE Life Sciences Ltd (WVE) reports a significant revenue increase and advances in RNA programs, despite facing competitive and regulatory challenges.
WAVE Life Sciences (NASDAQ:WVE) outlined progress across its lead cardiometabolic and RNA editing programs during its first-quarter 2026 earnings call, highlighting plans to start a Phase IIa obesity study this quarter and to present additional clinical data for its alpha-1 antitrypsin deficiency (A